The original success of Viagra undeniably reshaped the medication landscape, but placing funds in companies primarily reliant on off-patent versions presents a challenging picture. While early earnings were impressive, the end of patents and the emergence of discounted alternatives have diminished sales. Consequently, a thorough assessment of more